Last Close
May 15  •  04:00PM ET
0.4902
Dollar change
-0.0231
Percentage change
-4.50
%
Index
-
P/E
-
EPS (ttm)
-1.19
Insider Own
3.59%
Shs Outstand
39.98M
Perf Week
-12.62%
Market Cap
19.11M
Forward P/E
-
EPS next Y
-1.01
Insider Trans
0.72%
Shs Float
37.58M
Perf Month
-17.07%
Enterprise Value
5.45M
PEG
-
EPS next Q
-0.41
Inst Own
38.06%
Perf Quarter
-57.37%
Income
-21.16M
P/S
2.71
EPS this Y
-172.41%
Inst Trans
0.57%
Perf Half Y
-60.15%
Sales
7.06M
P/B
1.54
EPS next Y
35.76%
ROA
-61.34%
Perf YTD
-50.34%
Book/sh
0.32
P/C
1.27
EPS next 5Y
-27.42%
ROE
-693.93%
52W High
3.13 -84.34%
Perf Year
-75.49%
Cash/sh
0.38
P/FCF
-
EPS past 3/5Y
63.79% 45.78%
ROIC
-165.16%
52W Low
0.49 0.02%
Perf 3Y
-97.33%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-2.42% -2.71%
Gross Margin
97.89%
Volatility
7.44% 8.62%
Perf 5Y
-99.82%
Dividend TTM
-
EV/Sales
0.77
EPS Y/Y TTM
80.84%
Oper. Margin
-485.12%
ATR (14)
0.05
Perf 10Y
-99.71%
Dividend Ex-Date
-
Quick Ratio
1.11
Sales Y/Y TTM
-36.95%
Profit Margin
-299.66%
RSI (14)
34.71
Dividend Gr. 3/5Y
- -
Current Ratio
1.11
EPS Q/Q
0.01%
SMA20
-14.46%
Beta
3.03
Payout
-
Debt/Eq
0.11
Sales Q/Q
-100.00%
SMA50
-25.16%
Rel Volume
0.59
Prev Close
0.51
Employees
24
LT Debt/Eq
0.01
SMA200
-58.01%
Avg Volume
415.96K
Price
0.49
IPO
Aug 01, 2000
Option/Short
No / Yes
Trades
Volume
244,860
Change
-4.50%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
May-13-26 08:30AM
01:02AM
May-12-26 04:10PM
04:00PM
May-05-26 05:11PM
11:02PM Loading…
Mar-19-26 11:02PM
08:12PM
04:11PM
04:00PM
Mar-12-26 04:27PM
Jan-09-26 08:00AM
Jan-07-26 08:45AM
Dec-09-25 08:00AM
Nov-14-25 09:26AM
Nov-07-25 12:02AM
05:10PM Loading…
Nov-06-25 05:10PM
04:08PM
04:00PM
Oct-30-25 04:00PM
Oct-03-25 04:00PM
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM
Aug-04-25 10:13AM
Jul-29-25 08:30AM
Jul-02-25 08:32AM
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM Loading…
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
May-01-25 10:01AM
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
PresidentMr. James E. Dentzer
M.B.A.Ms. Diantha Duvall CPA
Chief Development OfficerDr. Jonathan B. Zung Ph.D.
Vice President of Technology Management & Intellectual PropertyMr. Mark W. Noel
Ph.D.Dr. Robert E. Martell M.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM